New Market Research Report: Netherlands Pharmaceuticals & Healthcare Report Q4 2014

The contraction of the Dutch economy during the first quarter of 2014 casts doubt on the durability of its recovery. The government will continue with austerity measures to meet the terms of EU budget criteria and further restrictions on drug expenditure look likely, particularly on essential medicines. Although healthcare expenditure continues to increase (in local currency terms), we maintain our view that additional caps on medicines prices will work to create a subdued outlook for patented and generic drugmakers operating in the country.

Headline Expenditure Projections

* Pharmaceuticals: EUR6.09bn (USD8.04bn) in 2013 to EUR5.89bn (USD7.90bn) in 2014; -3.2% in local currency terms and -1.7% in US dollar terms.
* Healthcare: EUR70.34bn (USD92.85bn) in 2013 to EUR71.31bn (USD95.55bn) in 2014; 1.4% in local currency terms and 2.9% in US dollar terms.

Risk/Reward Ratings

Full Report Details at
- http://www.fastmr.com/prod/861880_netherlands_pharmaceuticals_healthcare_report_q4.aspx?afid=301

The Netherlands continues to rank in the lower half of BMI's Pharmaceutical Risk/Reward Ratings (RRRs) for the 15 key Western European markets, falling one place to 12 ^th in our ratings for Q414. The country fell from eighth in Q413. At 65, its overall RRR score remains slightly below the regional average of 68. This was the result of the rise of Finland and the incorporation of Denmark in our ratings system, both of which overtook the Netherlands. While the country offers drugmakers a relatively low-risk operating environment, poor market prospects - due to pressures on pricing and reimbursement and the market's maturity - will continue to weigh down the country's overall standing.

Key Trends And Developments

July

Salix Pharmaceuticals and Pharming Group have reported the FDA approval of Ruconest (C1 esterase inhibitor [recombinant]) 50 IU/kg for the treatment of acute angio-oedema (AO) attacks in adult and adolescent patients with hereditary AO (HAO). Because of the limited number of patients with laryngeal attacks, effectiveness was not established in HAO patients with...

The Netherlands Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Netherlands Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Dutch pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Netherlands to test other views - a key input for successful budgeting and strategic business planning in the Dutch pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Kenya Pharmaceuticals & Healthcare Report Q4 2014
- Mexico Pharmaceuticals & Healthcare Report Q4 2014
- Thailand Pharmaceuticals & Healthcare Report Q4 2014
- Australia Pharmaceuticals & Healthcare Report Q4 2014